I'm really having a hard time with your post. You combined two things, FDA and oversea contracts, as if they somehow connected, and they are not as they are separated markets. You then suggest that shareholders should not expect any kind of market cap recovery in the next few months as in your eyes the company has no revenue prospects. I'm not sure if you are purposely or conveniently or unintentionally confusing stock price market pressures - supply and demand - with the true market value of the Company. They are not intertwined perfectly. Stocks wouldn't be "over" or "under" valued if that were the case. There would be no money to make in the market if price of holding were properly valued to Company's true valuation. And we know that none of us would be here if there was no money to be made on these volatility market mood swings of when the pendulum swings between over and under true value. The fact is that stocks trade simply on perception, whether "real" or "imagined" and those perceptions affect shareholder stock interest. And right now stock supply has been too high to meet shareholders demand interest. Demand interest has been lack luster and so the stock has fallen to the Company being valued at a mere $150K. It's priced for bankruptcy auction, seriously. The stock may trade at $.0048 today, and it may trade lower tomorrow, as insane as I think that may be to give away shares there, some shareholders will. Fear sells. But that doesn't mean the Company should only be worth less than quarterly revenue! Maybe it should be worth less (if failure to keep the lights on is days away - though I doubt this, as they delayed creditors). Maybe it should be worth more (I perceive this to be the case, obviously). The price of a penny stock can correct over night and go up a few thousand percent if the stock is wrongly priced. Until quarterly earnings is upon us, we won't know if the current stock price demonstrate the Company's fair value. Anyway, that's number one.
Number two, the FDA request for another trials is one of the reasons for the over correction market opportunity is upon us today (toxic debt is another; thankfully restructured now -- though remnants remains, the repercussions we see today ). The US market is nothing but a way-in-the-future goal. The market understands this. It is the reason the stock has over corrected to the downside, as there isn't much for shareholders to cling to in the short term. The Company valuation shouldn't have the any hint of an FDA product approval in it, at all. And at this point in time, with a market cap of $150k, it does not. That potential eventual US product approval is a meaningless target at this point and it shouldn't be part of any valuation discussion because their survival is not dependent on it. Until the Company has money to run an FDA trial, or a way to raise funds, it won't attempt to increase their quarterly burn rate. In fact, cost will go down as they stall that process. Consider that FDA pursuit a "dream wish" at this point in time. They know that. Possible investors who visit this board should know that too. As such there will be no raise in the next few months to fund an FDA trial. No reason to increase the share count for any other purpose than evade bankruptcy. No reason for an FDA trial to affect any R/S scenario. The Company focus at this point in merely survival and growth in other markets.
Now that said, the Company made it very clear back in March (Letter to shareholders) that their strategic direction, at least for the time being, is to focus on markets that they can sell LuViva Devices and Disposals. However that "razor/razor blade" sales model is not priced into their current valuation. At all. The Company has begun to come through on those contracts, and it is evident because revenue growth QoQ, YoY. See SEC statement below [mine].
"May 19, 2016 Guided Therapeutics Reports Record First Quarter 2016 Results Key Highlights:
* $262,000 of sales in 1Q 2016, a 106% increase from 2015 * Record number of disposable LuViva® Cervical Guides shipped in Q1 * Nearing 100 LuVivas shipped worldwide * Continued growth in the Middle East and Southeast Asia * Sale of 5 LuViva devices approved by Nairobi County, Kenya, for screening * Expanded distribution in Latin America * Negotiations with potential Chinese and Indian partners progressing
Guided Therapeutics, Inc. (OTCQB:GTHP) today announced its operating results for the first quarter ended March 31, 2016.
Sales Revenue, Cost of Sales and Gross Profit (Loss) from Devices and Disposables: Sales revenue from the sale of LuViva devices and disposables for the three months ended March 31, 2016, was $262,000, a 106% increase compared to the same period in 2015. Related costs of sales and net realizable value expenses were approximately $68,000, which resulted in a gross profit of approximately $194,000 for the first quarter of 2016. For the same period in 2015, approximately $127,000 in sales revenue was offset by approximately $107,000 in related costs of sales, resulting in a gross loss on devices and disposables of approximately $20,000. The increase from gross loss to gross profit was due to increased sales of disposables with the Company’s primary distributor, which carry a higher profit margin than device sales.
Research and Development Expenses: Research and development expenses decreased to approximately $290,000 for the three months ended March 31, 2016, compared to $373,000 for the same period in 2015. The decrease, of approximately $83,000, was primarily due to a slight decrease in payroll expenses.
Sales and Marketing Expenses: Sales and marketing expenses were approximately $117,000 during the three months ended March 31, 2016, compared to $172,000 for the same period in 2015. The decrease was primarily due to Company-wide expense reduction and cost savings efforts.
General and Administrative Expenses: General and administrative expenses decreased to approximately $917,000 during the three months ended March 31, 2016, compared to approximately $963,000 for the same period in 2015. The decrease of approximately $46,000, or 5.0%, was primarily related to lower compensation and option expenses incurred during the same period.
Other Income: Other income for the three months ended March 31, 2016, was approximately $23,000, compared to other income of approximately $21,000 for the three months ended March 31, 2015.
Interest Expense: Interest expense decreased to approximately $158,000 for the three months ended March 31, 2016, as compared to approximately $492,000 for the same period in 2015, primarily due to amortization of debt discount and debt issuance costs that were higher for the same period in 2015.
Fair Value of Warrants Expense: Fair value of warrants expense recovery was approximately $1,395,000 for the three months ended March 31, 2016, as compared to approximately $714,000 for the same period in 2015.
Net income was approximately $130,000 during the three months ended March 31, 2016, compared to a net loss of $1,245,000 for the same period in 2015, for the reasons outlined above. Preferred stock dividends was approximately $470,000 during the three months ended March 31, 2016, compared to $31,000 for the same period in 2015. Basic Net loss per share, was $0.11 for the three months ended March 31, 2016, and $1.31 for the same period in 2015. Diluted Net loss per share, was $0.00 for the three months ended March 31, 2016, and $1.31 for the same period in 2015.
Cash on hand at March 31, 2016, was approximately $56,000, as compared to approximately $35,000 at December 31, 2015. Net inventory on hand at the end of the quarter was approximately $1.3 million. The Company continues to manage cash and liquidity with austerity.
“The first quarter was a record for shipping single-use disposable LuViva cervical guides with almost 24,000 going to our Turkish distributor,” said Gene Cartwright, Chief Executive Officer of Guided Therapeutics. “We also shipped LuViva devices to Saudi Arabia and Indonesia during the quarter, bringing to 10 the number of units in the Middle East and 15 in Southeast Asia. As of the end of the first quarter, we shipped a total of 97 LuViva devices and approximately 60,000 disposable cervical guides, worldwide.”
[The contract calls for 450 LuVivas and 450,000 single-use Cervical Guides to be supplied by Guided Therapeutics over three and a half years beginning in the third quarter of 2015 and running through 2018. The delivery schedule calls for 50 LuVivas and 50,000 disposables in the remainder of calendar year 2015 and 200 LuVivas and 200,000 disposables in calendar year 2016 with the remaining 200 LuVivas and 200,000 Cervical Guides evenly distributed over the last two years of the contract.]
“During the first quarter, we received notification that the Health Services Sector of Nairobi County, Kenya, has agreed to purchase an additional five LuViva units for use in the agency’s cervical cancer screening program. The planned purchase brings to six the number of LuVivas ordered by Nairobi County, which is the largest population center in East Africa with approximately 900,000 screening-aged women,” Mr. Cartwright said.
“Finally, we expanded our distribution in Latin America to include the Dominican Republic in the first quarter and subsequently shipped our first unit there,” Mr. Cartwright said. “We continue to negotiate with potential partners for distribution and manufacturing rights in China, and are in late stage discussions with a partner for India.” "--- GTHP
So I completely disagree with your assertion as not to expect anything to come of the it. The contracts are already in place. It has NOTHING to do with the FDA so to combine the two and make it though as they are connected, and then to suggest that shareholders shouldn't expect any company valuation for those oversea contracts is simply a conjecture statement, and a misguided one in my humble opinion. You may perceive the market cap value as $.000 but this company earns revenue, it has a growing pipeline, and those shouldn't be discounted and ignored as they are currently not included in the market cap.
Now, where the stock might trade for the short term, maybe you'll be right. GLTUA
The reason this is going down and has been going down is because the idiots running the company gave us a 3 year heads up on a rs. Nobody in their right minds would ever invest in this garbage long term with that hovering over our heads. Management obviously doesn't care about their shareholders otherwise that would have never been released until they planned on doing the rs. Look where the stock has gone in a week. Down like 60%. Management is terrible here and they don't care about shareholders.
News 
Market Data 
Discover 
AI
